Preclinical assessment of nuzefatide pevedotin (nuzefa; formerly BT5528) anti-tumor activity in cell-line-derived xenograft models of head and neck squamous cell carcinoma

We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in “Cookie Settings”.